BPL-003 Phase 2a试验 - BPL-003 Phase 2a试验是一项开放标签研究，旨在研究BPL-003作为单药治疗和SSRIs的辅助治疗在治疗抗药性抑郁症患者中的效果[1] - BPL-003单药治疗第一部分的初步结果显示，单剂量的BPL-003安全耐受性良好，具有快速持久的抗抑郁效果，持续至剂量后的12周[2] - BPL-003 Phase 2a试验的第二部分将研究正在接受SSRI抗抑郁药物治疗的患者接受单剂量BPL-003的效果，第一位患者已在该部分接受剂量，初步结果预计在2025年上半年公布[3] Beckley Psytech的BPL-003 Phase 2a研究 - atai生命科学宣布Beckley Psytech的BPL-003 Phase 2a研究的第二部分已经开始，评估BPL-003在抗药性抑郁症患者中的效果[4]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

BPL-003药物特性 - Beckley Psytech开发的BPL-003是一种新型的受专利保护的苯甲酸盐制剂，通过鼻腔给药[1] - BPL-003在健康参与者中单剂量达到12毫克时，显示出安全、耐受性良好，且具有可预测的药代动力学特性[2] - 主观幻觉效应与5-MeO-DMT暴露相关，具有快速发作和短暂持续时间，急性效应在两小时内消退[3] BPL-003第一阶段结果 - atai Life Sciences宣布了Beckley Psytech的BPL-003的第一阶段结果，显示其安全、耐受性良好，并具有潜力作为可扩展的干预性治疗[4]

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus on psychedelic-based treatments for depression.   CEO and co-founder Florian Brand joined Proactive to discuss the company’s recent milestones including encouraging clinical trial results, what to expect from its ongoing research programs and upcoming catalysts for both the company and the broader psychedelics sector. Proactive: In 2023, there was a big focus on psyche ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-40493 ATAI Life Sciences N.V. (Exact name of registrant as specified in its charter) The Netherlands Not Applicable (State or other ...

Exhibit 99.1 atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights • Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato® • Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant ef ect through three months in TRD patients; top-line results from a c ...

The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai's proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being developed as a rapid-acting and durable antidepressant for treatment resistant depression, which affects approximately 100 million people globallyVLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interve ...

公司使命 - atai的使命是通过有效开发创新疗法来治疗抑郁症、焦虑症、成瘾和其他心理健康障碍[3] 公司愿景 - atai的愿景是治愈心理健康障碍，让每个人都能过上更充实的生活[5]

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three y ...